Patients not patents: Drug research and development as a public enterprise

Gøtzsche, Peter C

doi:10.1111/eci.12875

Cited by 11 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changes in the way this Agency works are imperative to allow for a public initiative like the European Salk Institute to prosper. 21…”

Section: Institutional Architecture and Governancementioning

confidence: 99%

A European Salk Institute Could Ensure Accessible and Affordable Medicines

De Ceukelaire,

Joye

2024

International Journal of Social Determinants of Health and Heal

View full text Add to dashboard Cite

Many researchers, consumer groups, activists and civil society organizations agree that the pharmaceutical sector has been left too much to the private sector, which is solely driven by a profit motive. Therefore, it is imperative to take a bold initiative to turn the idea of medicine, pharmaceutical products, and health technology as a common good into a reality. We propose to establish a European institute that can oversee an ambitious research portfolio. This institute can provide research grants or do in-house research but, in any case, any intellectual property rights emanating from the research will have to be shared in the interest of the public good. A collective knowledge pool, where all results and technological knowledge are gathered and shared, will likewise be part of the institute. Any final product developed within the Institute will be subject to an open license. We ensure that all necessary data and information remain public and that know-how about the production of a medicine can be passed on to those who need it. Finally, this institute should have a focus on production and distribution. Price, quality, availability and even working conditions of the staff will be criteria in any bidding process.

show abstract

“…Changes in the way this Agency works are imperative to allow for a public initiative like the European Salk Institute to prosper. 21…”

Section: Institutional Architecture and Governancementioning

confidence: 99%

A European Salk Institute Could Ensure Accessible and Affordable Medicines

De Ceukelaire,

Joye

2024

International Journal of Social Determinants of Health and Heal

View full text Add to dashboard Cite

show abstract

“…Raj misquotes me when he asserts that I was not the first to envision a future without patents. Of course, I wasn't but in the working group I participated in, I coined the idea of a future without patents and with public development of drugs . The chair found these ideas far‐fetched and became very surprised when it turned out that 10 of the 30 invited people were willing to join me.…”

mentioning

confidence: 99%

“…In response to my paper, where I call for abolishment of patents and for drug research and development as a public enterprise, Raj asserts that there is an increase in novel drug discoveries. The fact is that even the drug industry laments that drug innovation has dried out, which is why they buy start‐up companies.…”

mentioning

confidence: 99%

A totally new system is needed for drug research and development

Gøtzsche

2018

Eur J Clin Investigation

Self Cite

View full text Add to dashboard Cite

Pharmaceutical drug development: high drug prices and the hidden role of public funding

Annett¹

2020

BIOLOGIA FUTURA

View full text Add to dashboard Cite

In 2019 the record for the most expensive drug was broken at US$2.1 million per patient. The high costs of new drugs are justified by the pharmaceutical industry as the expense required for maintaining research and development (R&D) pipelines. However, this does not take into account that globally the public pays for between one to two thirds of upfront R&D costs through taxpayers or charitable donations. Governments are effectively paying twice for medicines; first through R&D and then paying the high prices upon approval. High drug prices distort research priorities, emphasising financial gains and not health gains. In this manuscript, issues surrounding the current patent based drug development model, public funding of research and pharmaceutical lobbing will be addressed. Finally, innovations in drug development to improve public health needs and guaranteeing medication access to patients will be explored.

show abstract

Patients not patents: Drug research and development as a public enterprise

Cited by 11 publications

References 47 publications

A European Salk Institute Could Ensure Accessible and Affordable Medicines

A European Salk Institute Could Ensure Accessible and Affordable Medicines

A totally new system is needed for drug research and development

Pharmaceutical drug development: high drug prices and the hidden role of public funding

Contact Info

Product

Resources

About